Takeda Pharmaceutical Company Ltd

🇸🇪Sweden

Country: 🇸🇪Sweden

Ownership: -

Established: 1925-01-01

Employees: -

Market Cap: $47.5B

Website: http://www.takeda.co.jp/

Clinical Trials

A Study to Describe Treatment Patterns and Disease Control in Participants With cHL and sALCL in Routine Clinical Practice in the Russian Federation

Completed

Conditions: Hodgkin Disease
Lymphoma, Large-cell, Anaplastic

First Posted Date: 2019-05-08

Last Posted Date: 2024-07-15

Lead Sponsor: Takeda

Target Recruit Count: 2000

Registration Number: NCT03942263

Locations: 🇷🇺
State Budget Public Health Institution "Regional Oncological Dispensary", Irkutsk, Russian Federation
🇷🇺
The State Budgetary Institution of Healthcare "Regional Oncologic Dispensary", Penza, Russian Federation
🇷🇺
Kaluga Regional Clinical Oncologic Dispensary, Kaluga, Russian Federation

and more 47 locations

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TAK-994 in Healthy Participants

Phase 1

Completed

Conditions: Healthy Participants

Interventions: Drug: TAK-994
Drug: TAK-994 Placebo

First Posted Date: 2019-05-01

Last Posted Date: 2020-06-24

Lead Sponsor: Takeda

Target Recruit Count: 121

Registration Number: NCT03933488

Locations: 🇺🇸
Parexel International, Glendale, California, United States
🇺🇸
PRA Health Sciences, Salt Lake City, Utah, United States

A Study of TAK-954 to Treat Gastrointestinal Dysfunction in Adults After Surgery

Phase 2

Completed

Conditions: Postoperative Gastrointestinal Dysfunction

Interventions: Drug: TAK-954 Placebo
Drug: TAK-954

First Posted Date: 2019-02-01

Last Posted Date: 2023-06-23

Lead Sponsor: Takeda

Target Recruit Count: 209

Registration Number: NCT03827655

Locations: 🇩🇪
Universitatsklinikum Freiburg, Freiburg, Baden-wuerttemberg, Germany
🇩🇪
Sankt Josef-Hospital, Bochum, Nordrhein-westfalen, Germany
🇩🇪
Universitatsklinikum Mannheim, Mannheim, Baden-wuerttemberg, Germany

and more 22 locations

Specified Drug-Use Survey on Vedolizumab for IV Infusion 300 mg [Ulcerative Colitis]

Completed

Conditions: Ulcerative Colitis

Interventions: Drug: Vedolizumab

First Posted Date: 2019-01-31

Last Posted Date: 2024-11-07

Lead Sponsor: Takeda

Target Recruit Count: 1096

Registration Number: NCT03824561

Locations: 🇯🇵
Takeda Selected Site, Tokyo, Japan

Post Marketing Surveillance Study for ADYNOVATE in South Korea

Completed

Conditions: Hemophilia A

Interventions: Biological: ADYNOVATE

First Posted Date: 2019-01-31

Last Posted Date: 2024-02-26

Lead Sponsor: Takeda

Target Recruit Count: 341

Registration Number: NCT03824522

Locations: 🇰🇷
Kyungpook National University Hospital, Daegu, Korea, Republic of
🇰🇷
Daegu Catholic University Medical Center, Daegu, Korea, Republic of
🇰🇷
Kyungpook National University Chilgok Hospital, Daegu, Korea, Republic of

and more 5 locations

A Study of Pevonedistat in People With Blood Cancers or Solid Tumors With Kidney or Liver Problems

Phase 1

Completed

Conditions: Liver Disease
Myelodysplastic Syndromes
Leukemia, Myelomonocytic, Chronic
Leukemia, Myeloid, Acute
Renal Insufficiency
Neoplasms

Interventions: Drug: Azacitidine
Drug: Pevonedistat

First Posted Date: 2019-01-23

Last Posted Date: 2022-12-09

Lead Sponsor: Takeda

Target Recruit Count: 17

Registration Number: NCT03814005

Locations: 🇪🇸
ICO lHospitalet Hospital Duran i Reynals, LHospitalet de Llobregat, Barcelona, Spain
🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States
🇺🇸
University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States

and more 5 locations

A Study of Mobocertinib in Japanese Adults With Non-Small Cell Lung Cancer

Phase 1

Active, not recruiting

Conditions: Non-Small Cell Lung Cancer

Interventions: Drug: Mobocertinib

First Posted Date: 2019-01-17

Last Posted Date: 2024-03-15

Lead Sponsor: Takeda

Target Recruit Count: 53

Registration Number: NCT03807778

Locations: 🇯🇵
National Cancer Center Hospital East, Kashiwa, Chiba, Japan
🇯🇵
Hokkaido Cancer Center, Sapporo, Hokkaido, Japan
🇯🇵
Aichi Cancer Center Hospital, Nagoya, Aichi, Japan

and more 22 locations

A Bioequivalence (BE) Study of TAK-438 Orally Disintegrating (OD) Tablet

Phase 1

Completed

Conditions: Japanese Healthy Adult Male

Interventions: Drug: TAK-438 OD
Drug: TAK-438

First Posted Date: 2019-01-17

Last Posted Date: 2020-04-07

Lead Sponsor: Takeda

Target Recruit Count: 48

Registration Number: NCT03808493

Locations: 🇯🇵
Sekino Clinical Pharmacology Clininc, Toshima-ku, Tokyo, Japan

A Study to Compare the Bioavailability (BA) of Dexlansoprazole Delayed-release Capsules

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: 60 mg dexlansoprazole capsules manufactured at TOB
Drug: 30 mg dexlansoprazole capsules manufactured at TOB
Drug: 30 mg dexlansoprazole capsules manufactured at TPC
Drug: 60 mg dexlansoprazole capsules manufactured at TPC

First Posted Date: 2019-01-11

Last Posted Date: 2020-03-19

Lead Sponsor: Takeda

Target Recruit Count: 122

Registration Number: NCT03801148

Locations: 🇺🇸
Celerion, Tempe, Arizona, United States

Immunogenicity and Safety of Tetravalent Dengue Vaccine (TDV) at the End of Shelf Life in Healthy Adults

Phase 3

Completed

Conditions: Dengue Fever

Interventions: Biological: Tetravalent Dengue Vaccine (TDV)

First Posted Date: 2018-12-11

Last Posted Date: 2021-06-07

Lead Sponsor: Takeda

Target Recruit Count: 200

Registration Number: NCT03771963

Locations: 🇺🇸
Anaheim Clinical Trials, LLC, Anaheim, California, United States
🇺🇸
Hutchinson Clinic, Hutchinson, Kansas, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy